HC Wainwright & Co. Reiterates Buy on Deciphera Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Deciphera Pharmaceuticals (NASDAQ:DCPH) and maintained a price target of $25.
August 10, 2023 | 11:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Deciphera Pharmaceuticals' stock has been reiterated as a 'Buy' by HC Wainwright & Co. with a maintained price target of $25.
The reiteration of a 'Buy' rating and maintenance of a $25 price target by HC Wainwright & Co. indicates a positive outlook for Deciphera Pharmaceuticals. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100